Jazz Pharmaceuticals Announces Third Quarter 2016 Financial Results
"We have made substantial progress towards achieving our corporate objectives for 2016, delivering solid top-line growth in our commercial business, investing in broadening our hematology/oncology portfolio with the completion of the Celator acquisition and increasing our investments in R&D," said
GAAP net income attributable to
Adjusted net income attributable to
Financial Highlights |
|||||||||||||||||||||
Three Months Ended |
Nine Months Ended |
||||||||||||||||||||
(In thousands, except per share amounts and percentages) |
2016 |
2015 |
Change |
2016 |
2015 |
Change |
|||||||||||||||
Total revenues |
$ |
374,181 |
$ |
340,872 |
9.8 |
% |
$ |
1,091,352 |
$ |
983,922 |
10.9 |
% |
|||||||||
GAAP net income attributable to Jazz Pharmaceuticals plc |
$ |
87,145 |
$ |
87,960 |
(0.9) |
% |
$ |
272,548 |
$ |
246,774 |
10.4 |
% |
|||||||||
Adjusted net income attributable to Jazz Pharmaceuticals plc1 |
$ |
158,470 |
$ |
159,302 |
(0.5) |
% |
$ |
453,931 |
$ |
418,968 |
8.3 |
% |
|||||||||
GAAP EPS attributable to Jazz Pharmaceuticals plc |
$ |
1.41 |
$ |
1.39 |
1.4 |
% |
$ |
4.40 |
$ |
3.91 |
12.5 |
% |
|||||||||
Adjusted EPS attributable to Jazz Pharmaceuticals plc1 |
$ |
2.57 |
$ |
2.52 |
2.0 |
% |
$ |
7.32 |
$ |
6.64 |
10.2 |
% |
1. |
Commencing with the second quarter of 2016, the company modified the calculation of its non-GAAP income tax provision in connection with the Securities and Exchange Commission's May 2016 guidance pertaining to non-GAAP financial measures. This modification is reflected in the company's 2015 and 2016 non-GAAP interim period results and full-year 2016 financial guidance. See "Non-GAAP Financial Measures" below. The modification did not have a material effect on the adjusted net income attributable to Jazz Pharmaceuticals plc or adjusted EPS for the three months ended September 30, 2015. The modification resulted in the reduction of adjusted net income attributable to Jazz Pharmaceuticals plc by $17.6 million, or $0.28 per diluted share, compared to the amount previously reported for the nine months ended September 30, 2015. |
Total Revenues |
|||||||||||||||
Three Months Ended |
Nine Months Ended |
||||||||||||||
(In thousands) |
2016 |
2015 |
2016 |
2015 |
|||||||||||
Xyrem® (sodium oxybate) oral solution |
$ |
285,907 |
$ |
242,899 |
$ |
816,412 |
$ |
703,435 |
|||||||
Erwinaze® / Erwinase® (asparaginase Erwinia chrysanthemi) |
42,986 |
56,317 |
143,907 |
152,821 |
|||||||||||
Defitelio® (defibrotide sodium) / defibrotide |
28,137 |
19,639 |
79,280 |
52,259 |
|||||||||||
Prialt® (ziconotide) intrathecal infusion |
8,783 |
6,042 |
23,065 |
19,944 |
|||||||||||
Psychiatry |
3,875 |
9,910 |
14,744 |
28,375 |
|||||||||||
Other |
1,933 |
3,947 |
7,239 |
21,061 |
|||||||||||
Product sales, net |
371,621 |
338,754 |
1,084,647 |
977,895 |
|||||||||||
Royalties and contract revenues |
2,560 |
2,118 |
6,705 |
6,027 |
|||||||||||
Total revenues |
$ |
374,181 |
$ |
340,872 |
$ |
1,091,352 |
$ |
983,922 |
Net product sales increased 10% in the third quarter of 2016 compared to the same period in 2015 due to higher net product sales of Xyrem and Defitelio.
Xyrem net product sales increased 18% in the third quarter of 2016 compared to the same period in 2015.
Erwinaze/Erwinase net product sales decreased 24% in the third quarter of 2016 compared to the same period in 2015 due to an Erwinaze supply interruption in the U.S. late in the third quarter of 2016. The company expects that it will continue to experience Erwinaze inventory and supply challenges, which have resulted, and are expected to continue to result, in temporary disruptions in the company's ability to supply certain markets, including the U.S.
Defitelio/defibrotide net product sales increased
Operating Expenses |
|||||||||||||||
Three Months Ended |
Nine Months Ended |
||||||||||||||
(In thousands, except percentages) |
2016 |
2015 |
2016 |
2015 |
|||||||||||
GAAP: |
|||||||||||||||
Cost of product sales |
$ |
24,311 |
$ |
28,385 |
$ |
71,730 |
$ |
78,496 |
|||||||
Gross margin |
93.5 |
% |
91.6 |
% |
93.4 |
% |
92.0 |
% |
|||||||
Selling, general and administrative |
$ |
124,368 |
$ |
104,044 |
$ |
375,751 |
$ |
323,564 |
|||||||
% of total revenues |
33.2 |
% |
30.5 |
% |
34.4 |
% |
32.9 |
% |
|||||||
Research and development |
$ |
47,796 |
$ |
50,784 |
$ |
118,139 |
$ |
105,798 |
|||||||
% of total revenues |
12.8 |
% |
14.9 |
% |
10.8 |
% |
10.8 |
% |
|||||||
Acquired in-process research and development |
$ |
15,000 |
$ |
— |
$ |
23,750 |
$ |
— |
Three Months Ended |
Nine Months Ended |
||||||||||||||
(In thousands, except percentages) |
2016 |
2015 |
2016 |
2015 |
|||||||||||
Non-GAAP adjusted: |
|||||||||||||||
Cost of product sales |
$ |
22,963 |
$ |
27,599 |
$ |
68,620 |
$ |
76,243 |
|||||||
Gross margin |
93.8 |
% |
91.9 |
% |
93.7 |
% |
92.2 |
% |
|||||||
Selling, general and administrative |
$ |
94,534 |
$ |
84,502 |
$ |
296,633 |
$ |
268,013 |
|||||||
% of total revenues |
25.3 |
% |
24.8 |
% |
27.2 |
% |
27.2 |
% |
|||||||
Research and development |
$ |
43,323 |
$ |
22,998 |
$ |
106,847 |
$ |
70,661 |
|||||||
% of total revenues |
11.6 |
% |
6.7 |
% |
9.8 |
% |
7.2 |
% |
Operating expenses changed over the prior year period primarily due to the following:
- Selling, general and administrative (SG&A) expenses increased in the third quarter of 2016 compared to the same period in 2015 on a GAAP and on a non-GAAP adjusted basis, primarily due to higher headcount and other expenses resulting from the expansion of the company's business. The increase on a GAAP basis was also driven by transaction and integration costs related to the Celator acquisition.
- Research and development (R&D) expenses on a GAAP basis decreased by
$3.0 million in the third quarter of 2016 compared to the same period in 2015. R&D expenses on a non-GAAP adjusted basis increased by$20.3 million primarily due to increased expenses for the development of JZP-110; increasing investments in line extensions for the company's existing products, including oxybate-related R&D programs and the initiation of a clinical study of defibrotide for the prevention of veno-occlusive disease (VOD); and costs related to the rolling new drug application (NDA) submission for VyxeosTM(cytarabine and daunorubicin liposome injection). The decrease in R&D expenses on a GAAP basis was primarily due to a$25.0 million milestone expense in the third quarter of 2015 in connection with the acceptance for filing by theU.S. Food and Drug Administration (FDA ) of the NDA for defibrotide, which was partially offset by the project related costs described above. - Acquired in-process research and development expense in the third quarter of 2016 related to upfront and option payments to
Pfenex Inc. under an agreement in which the company was granted worldwide rights to develop and commercialize multiple early-stage hematology product candidates.
Cash Flow and Balance Sheet
As of September 30, 2016, cash, cash equivalents and investments were
During the nine months ended
Recent Developments
In
In
During the third quarter of 2016, the company activated clinical sites in the Phase 3 study of defibrotide for the prevention of VOD in high-risk patients following hematopoietic stem cell transplantation.
In
2016 Financial Guidance
Revenues |
$1,485-$1,530 |
Total net product sales |
$1,477-$1,522 |
-Xyrem net sales* |
$1,100-$1,125 |
-Erwinaze/Erwinase net sales |
$190-$215 |
-Defitelio/defibrotide net sales* |
$105-$120 |
GAAP gross margin % |
93% |
Non-GAAP adjusted gross margin %1,4 |
93% |
GAAP SG&A expenses* |
$492-$517 |
Non-GAAP adjusted SG&A expenses*,2,4 |
$395-$405 |
GAAP R&D expenses* |
$159-$171 |
Non-GAAP adjusted R&D expenses*,3,4 |
$145-$155 |
GAAP net income per diluted share |
$5.66-$6.56 |
Non-GAAP adjusted net income per diluted share4 |
$9.90-$10.30 |
* Updated November 8, 2016. |
|||||||
1. |
Excludes $5 million of share-based compensation expense from estimated GAAP gross margin. |
||||||
2. |
Excludes $78-$86 million of share-based compensation expense, $13-$20 million of transaction and integration related costs and $6 million of expenses related to certain legal proceedings and restructuring from estimated GAAP SG&A expenses. |
||||||
3. |
Excludes $14-$16 million of share-based compensation expense from estimated GAAP R&D expenses. |
||||||
4. |
See "Non-GAAP Financial Measures" below. Reconciliations of non-GAAP adjusted guidance measures are included above and in the table titled "Reconciliation of GAAP to Non-GAAP Adjusted 2016 Net Income Guidance" provided on the last page of this press release. |
Conference Call Details
A replay of the conference call will be available through
About
Non-GAAP Financial Measures
To supplement
The company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts. In particular, the company believes that each of these non-GAAP financial measures, when considered together with the company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the company's results from period to period and to its forward-looking guidance, and to identify operating trends in the company's business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the company's financial performance.
These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the company's condensed consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; and the company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Likewise, the company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. In this regard, the company modified the calculation of its non-GAAP income tax provision commencing in the second quarter of 2016 and accordingly, the income tax effect of the adjustments between GAAP reported and non-GAAP adjusted results takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). For purposes of comparability, the non-GAAP income tax provision and the corresponding income tax adjustment to arrive at non-GAAP adjusted net income attributable to
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements, including, but not limited to, statements related to
JAZZ PHARMACEUTICALS PLC |
|||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME |
|||||||||||||||
(In thousands, except per share amounts) |
|||||||||||||||
(Unaudited) |
|||||||||||||||
Three Months Ended |
Nine Months Ended |
||||||||||||||
2016 |
2015 |
2016 |
2015 |
||||||||||||
Revenues: |
|||||||||||||||
Product sales, net |
$ |
371,621 |
$ |
338,754 |
$ |
1,084,647 |
$ |
977,895 |
|||||||
Royalties and contract revenues |
2,560 |
2,118 |
6,705 |
6,027 |
|||||||||||
Total revenues |
374,181 |
340,872 |
1,091,352 |
983,922 |
|||||||||||
Operating expenses: |
|||||||||||||||
Cost of product sales (excluding amortization of intangible assets) |
24,311 |
28,385 |
71,730 |
78,496 |
|||||||||||
Selling, general and administrative |
124,368 |
104,044 |
375,751 |
323,564 |
|||||||||||
Research and development |
47,796 |
50,784 |
118,139 |
105,798 |
|||||||||||
Acquired in-process research and development |
15,000 |
— |
23,750 |
— |
|||||||||||
Intangible asset amortization |
26,453 |
26,127 |
75,832 |
74,472 |
|||||||||||
Total operating expenses |
237,928 |
209,340 |
665,202 |
582,330 |
|||||||||||
Income from operations |
136,253 |
131,532 |
426,150 |
401,592 |
|||||||||||
Interest expense, net |
(18,498) |
(12,650) |
(42,811) |
(44,707) |
|||||||||||
Foreign currency loss |
(749) |
(977) |
(1,568) |
(646) |
|||||||||||
Loss on extinguishment and modification of debt |
(638) |
— |
(638) |
(16,815) |
|||||||||||
Income before income tax provision and equity in loss of investee, net of tax |
116,368 |
117,905 |
381,133 |
339,424 |
|||||||||||
Income tax provision |
29,120 |
29,945 |
108,482 |
92,651 |
|||||||||||
Equity in loss of investee, net of tax |
103 |
— |
103 |
— |
|||||||||||
Net income |
87,145 |
87,960 |
272,548 |
246,773 |
|||||||||||
Net loss attributable to noncontrolling interests, net of tax |
— |
— |
— |
(1) |
|||||||||||
Net income attributable to Jazz Pharmaceuticals plc |
$ |
87,145 |
$ |
87,960 |
$ |
272,548 |
$ |
246,774 |
|||||||
Net income attributable to Jazz Pharmaceuticals plc per ordinary share: |
|||||||||||||||
Basic |
$ |
1.44 |
$ |
1.43 |
$ |
4.49 |
$ |
4.04 |
|||||||
Diluted |
$ |
1.41 |
$ |
1.39 |
$ |
4.40 |
$ |
3.91 |
|||||||
Weighted-average ordinary shares used in per share calculations - basic |
60,437 |
61,435 |
60,692 |
61,145 |
|||||||||||
Weighted-average ordinary shares used in per share calculations - diluted |
61,644 |
63,154 |
61,983 |
63,072 |
JAZZ PHARMACEUTICALS PLC |
||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||||
(In thousands) |
||||||||
(Unaudited) |
||||||||
September 30, |
December 31, |
|||||||
ASSETS |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ |
366,567 |
$ |
988,785 |
||||
Investments |
59,418 |
— |
||||||
Accounts receivable, net of allowances |
238,072 |
209,685 |
||||||
Inventories |
32,351 |
19,451 |
||||||
Prepaid expenses |
23,304 |
20,699 |
||||||
Other current assets |
24,517 |
19,047 |
||||||
Total current assets |
744,229 |
1,257,667 |
||||||
Property and equipment, net |
99,898 |
85,572 |
||||||
Intangible assets, net |
3,110,439 |
1,185,606 |
||||||
Goodwill |
927,993 |
657,139 |
||||||
Deferred tax assets, net, non-current |
— |
122,863 |
||||||
Deferred financing costs |
10,258 |
7,209 |
||||||
Other non-current assets |
37,764 |
27,548 |
||||||
Total assets |
$ |
4,930,581 |
$ |
3,343,604 |
||||
LIABILITIES AND SHAREHOLDERS' EQUITY |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ |
17,626 |
$ |
21,807 |
||||
Accrued liabilities |
172,418 |
164,070 |
||||||
Current portion of long-term debt |
36,094 |
37,587 |
||||||
Income taxes payable |
5,222 |
1,808 |
||||||
Deferred revenue |
1,499 |
1,370 |
||||||
Total current liabilities |
232,859 |
226,642 |
||||||
Deferred revenue, non-current |
2,881 |
3,721 |
||||||
Long-term debt, less current portion |
2,147,379 |
1,150,857 |
||||||
Deferred tax liability, net, non-current |
725,358 |
294,485 |
||||||
Other non-current liabilities |
106,101 |
69,253 |
||||||
Total shareholders' equity |
1,716,003 |
1,598,646 |
||||||
Total liabilities and shareholders' equity |
$ |
4,930,581 |
$ |
3,343,604 |
JAZZ PHARMACEUTICALS PLC |
|||||||||||||||
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION |
|||||||||||||||
(In thousands, except per share amounts) |
|||||||||||||||
(Unaudited) |
|||||||||||||||
Three Months Ended |
Nine Months Ended |
||||||||||||||
2016 |
2015 |
2016 |
2015 |
||||||||||||
GAAP reported net income attributable to Jazz Pharmaceuticals plc |
$ |
87,145 |
$ |
87,960 |
$ |
272,548 |
$ |
246,774 |
|||||||
Intangible asset amortization |
26,453 |
26,127 |
75,832 |
74,472 |
|||||||||||
Share-based compensation expense |
24,874 |
23,114 |
74,490 |
67,233 |
|||||||||||
Upfront and milestone payments |
15,000 |
25,000 |
23,750 |
25,000 |
|||||||||||
Transaction and integration related costs |
10,781 |
— |
12,970 |
155 |
|||||||||||
Expenses related to certain legal proceedings and restructuring |
— |
— |
6,060 |
553 |
|||||||||||
Non-cash interest expense |
5,642 |
5,300 |
16,418 |
17,348 |
|||||||||||
Loss on extinguishment and modification of debt |
638 |
— |
638 |
16,815 |
|||||||||||
Income tax effect of adjustments (1) |
(12,063) |
(8,199) |
(28,775) |
(29,380) |
|||||||||||
Adjustments for amount attributable to noncontrolling interests (2) |
— |
— |
— |
(2) |
|||||||||||
Non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc |
$ |
158,470 |
$ |
159,302 |
$ |
453,931 |
$ |
418,968 |
|||||||
GAAP reported net income attributable to Jazz Pharmaceuticals plc per diluted share |
$ |
1.41 |
$ |
1.39 |
$ |
4.40 |
$ |
3.91 |
|||||||
Non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc per diluted share (3) |
$ |
2.57 |
$ |
2.52 |
$ |
7.32 |
$ |
6.64 |
|||||||
Weighted-average ordinary shares used in diluted per share calculations |
61,644 |
63,154 |
61,983 |
63,072 |
(1) |
The income tax effect of the adjustments between GAAP reported and non-GAAP adjusted net income takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). |
|||||
(2) |
The noncontrolling interests' share of the above adjustments as applicable. |
|||||
(3) |
Commencing with the company's earnings release for the second quarter of 2016, the company modified the calculation of its non-GAAP income tax provision. The modification did not have a material effect on non-GAAP adjusted EPS for the three months ended September 30, 2015. The modification resulted in the reduction of non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc per diluted share of $0.28 compared to the amount previously reported for the nine months ended September 30, 2015. See "Non-GAAP Financial Measures". |
JAZZ PHARMACEUTICALS PLC |
|||||||||||||||||||||||
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION |
|||||||||||||||||||||||
CERTAIN LINE ITEMS AND OTHER INFORMATION |
|||||||||||||||||||||||
(In thousands, except per share amounts and percentages) |
|||||||||||||||||||||||
(Unaudited) |
|||||||||||||||||||||||
Three Months Ended |
|||||||||||||||||||||||
September 30, 2016 |
September 30, 2015 |
||||||||||||||||||||||
GAAP |
Adjustments |
Non-GAAP |
GAAP |
Adjustments |
Non-GAAP |
||||||||||||||||||
Total revenues |
$ |
374,181 |
$ |
— |
$ |
374,181 |
$ |
340,872 |
$ |
— |
$ |
340,872 |
|||||||||||
Cost of product sales (excluding amortization of intangible assets) |
24,311 |
(1,348) |
(a) |
22,963 |
28,385 |
(786) |
(a) |
27,599 |
|||||||||||||||
Selling, general and administrative |
124,368 |
(29,834) |
(b) |
94,534 |
104,044 |
(19,542) |
(b) |
84,502 |
|||||||||||||||
Research and development |
47,796 |
(4,473) |
(c) |
43,323 |
50,784 |
(27,786) |
(c) |
22,998 |
|||||||||||||||
Acquired in-process research and development |
15,000 |
(15,000) |
— |
— |
— |
— |
|||||||||||||||||
Intangible asset amortization |
26,453 |
(26,453) |
— |
26,127 |
(26,127) |
— |
|||||||||||||||||
Interest expense, net |
18,498 |
(5,642) |
(d) |
12,856 |
12,650 |
(5,300) |
(d) |
7,350 |
|||||||||||||||
Foreign currency loss |
749 |
— |
749 |
977 |
— |
977 |
|||||||||||||||||
Loss on extinguishment and modification of debt |
638 |
(638) |
— |
— |
— |
— |
|||||||||||||||||
Income before income tax provision and equity in loss of investee, net of tax |
116,368 |
83,388 |
(e) |
199,756 |
117,905 |
79,541 |
(e) |
197,446 |
|||||||||||||||
Income tax provision |
29,120 |
12,063 |
(f) |
41,183 |
29,945 |
8,199 |
(f) |
38,144 |
|||||||||||||||
Effective tax rate (g) |
25.0 |
% |
20.6 |
% |
25.4 |
% |
19.3 |
% |
|||||||||||||||
Equity in loss of investee, net of tax |
103 |
— |
103 |
— |
— |
— |
|||||||||||||||||
Net income |
$ |
87,145 |
$ |
71,325 |
(h) |
$ |
158,470 |
$ |
87,960 |
$ |
71,342 |
(h) |
$ |
159,302 |
|||||||||
Net income per diluted share |
$ |
1.41 |
$ |
2.57 |
$ |
1.39 |
$ |
2.52 |
JAZZ PHARMACEUTICALS PLC |
|||||||||||||||||||||||
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION |
|||||||||||||||||||||||
CERTAIN LINE ITEMS AND OTHER INFORMATION |
|||||||||||||||||||||||
(In thousands, except per share amounts and percentages) |
|||||||||||||||||||||||
(Unaudited) |
|||||||||||||||||||||||
Nine Months Ended |
|||||||||||||||||||||||
September 30, 2016 |
September 30, 2015 |
||||||||||||||||||||||
GAAP |
Adjustments |
Non-GAAP |
GAAP |
Adjustments |
Non-GAAP |
||||||||||||||||||
Total revenues |
$ |
1,091,352 |
$ |
— |
$ |
1,091,352 |
$ |
983,922 |
$ |
— |
$ |
983,922 |
|||||||||||
Cost of product sales (excluding amortization of intangible assets) |
71,730 |
(3,110) |
(i) |
68,620 |
78,496 |
(2,253) |
(i) |
76,243 |
|||||||||||||||
Selling, general and administrative |
375,751 |
(79,118) |
(j) |
296,633 |
323,564 |
(55,551) |
(j) |
268,013 |
|||||||||||||||
Research and development |
118,139 |
(11,292) |
(k) |
106,847 |
105,798 |
(35,137) |
(k) |
70,661 |
|||||||||||||||
Acquired in-process research and development |
23,750 |
(23,750) |
— |
— |
— |
— |
|||||||||||||||||
Intangible asset amortization |
75,832 |
(75,832) |
— |
74,472 |
(74,472) |
— |
|||||||||||||||||
Interest expense, net |
42,811 |
(16,418) |
(d) |
26,393 |
44,707 |
(17,348) |
(d) |
27,359 |
|||||||||||||||
Foreign currency loss |
1,568 |
— |
1,568 |
646 |
— |
646 |
|||||||||||||||||
Loss on extinguishment and modification of debt |
638 |
(638) |
— |
16,815 |
(16,815) |
— |
|||||||||||||||||
Income before income tax provision and equity in loss of investee, net of tax |
381,133 |
210,158 |
(l) |
591,291 |
339,424 |
201,576 |
(l) |
541,000 |
|||||||||||||||
Income tax provision |
108,482 |
28,775 |
(f) |
137,257 |
92,651 |
29,380 |
(f) |
122,031 |
|||||||||||||||
Effective tax rate (g) |
28.5 |
% |
23.2 |
% |
27.3 |
% |
22.6 |
% |
|||||||||||||||
Equity in loss of investee, net of tax |
103 |
— |
103 |
— |
— |
— |
|||||||||||||||||
Net income |
272,548 |
181,383 |
(m) |
453,931 |
246,773 |
172,196 |
(m) |
418,969 |
|||||||||||||||
Net income (loss) attributable to noncontrolling interests, net of tax |
— |
— |
(n) |
— |
(1) |
2 |
(n) |
1 |
|||||||||||||||
Net income attributable to Jazz Pharmaceuticals plc |
$ |
272,548 |
$ |
181,383 |
(o) |
$ |
453,931 |
$ |
246,774 |
$ |
172,194 |
(o) |
$ |
418,968 |
|||||||||
Net income attributable to Jazz Pharmaceuticals plc per diluted share |
$ |
4.40 |
$ |
7.32 |
$ |
3.91 |
$ |
6.64 |
|||||||||||||||
Explanation of Adjustments and Certain Line Items (in thousands): |
|
(a) |
Share-based compensation expense of $1,307 and $786 and transaction and integration related costs of $41 and $0 for the three months ended September 30, 2016 and 2015, respectively. |
(b) |
Share-based compensation expense of $19,511 and $19,542 and transaction and integration related costs of $10,323 and $0 for the three months ended September 30, 2016 and 2015, respectively. |
(c) |
Share-based compensation expense of $4,056 and $2,786, transaction and integration related costs of $417 and $0 and milestone of $0 and $25,000 for the three months ended September 30, 2016 and 2015, respectively. |
(d) |
Non-cash interest expense associated with debt discount and debt issuance costs for the respective three- and nine-month periods. |
(e) |
Sum of adjustments (a) through (d) plus the adjustments for acquired in-process research and development, intangible asset amortization and loss on extinguishment and modification of debt, as applicable, for the respective three-month period. |
(f) |
Income tax effect of the adjustments between GAAP reported and non-GAAP adjusted net income takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s) in the respective three-and nine-month periods. |
(g) |
Income tax provision divided by income before income tax provision and equity in loss of investee, net of tax, for the respective three- and nine-month periods. |
(h) |
Net of adjustments (e) and (f) for the respective three-month period. |
(i) |
Share-based compensation expense of $2,959 and $2,253, expenses related to certain legal proceedings and restructuring of $110 and $0 and transaction and integration related costs of $41 and $0 for the nine months ended September 30, 2016 and 2015, respectively. |
(j) |
Share-based compensation expense of $60,664 and $54,843, expenses related to certain legal proceedings and restructuring of $5,950 and $553 and transaction and integration related costs of $12,504 and $155 for the nine months ended September 30, 2016 and 2015, respectively. |
(k) |
Share-based compensation expense of $10,867 and $10,137, transaction and integration related costs of $425 and $0 and milestone of $0 and $25,000 for the nine months ended September 30, 2016 and 2015, respectively. |
(l) |
Sum of adjustments (i), (j), (k) and (d) plus the adjustments for acquired in-process research and development expenses, intangible asset amortization and loss on extinguishment and modification of debt, as applicable, for the respective nine-month period. |
(m) |
Net of adjustments (l) and (f) for the respective nine-month period. |
(n) |
Adjustments for amount attributable to noncontrolling interests for the respective nine-month period. |
(o) |
Net of adjustments (m) and (n) for the respective nine-month period. |
JAZZ PHARMACEUTICALS PLC |
|
GAAP net income |
$351 - $407 |
Intangible asset amortization |
100 - 110 |
Share-based compensation expense |
97 - 107 |
Upfront and milestone payments |
24 |
Transaction and integration related costs* |
13 - 20 |
Expenses related to certain legal proceedings and restructuring |
6 |
Non-cash interest expense |
20 - 24 |
Loss on extinguishment and modification of debt* |
1 |
Income tax effect of adjustments |
(37) - (27) |
Non-GAAP adjusted net income |
$615 - $640 |
GAAP net income per diluted share |
$5.66-$6.56 |
Non-GAAP adjusted net income per diluted share |
$9.90-$10.30 |
Weighted-average ordinary shares used in per share calculations |
62 |
* Updated November 8, 2016. |
Logo - http://photos.prnewswire.com/prnh/20150930/272253LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-third-quarter-2016-financial-results-300359341.html
SOURCE
Investors, Kathee Littrell, Vice President, Investor Relations, Jazz Pharmaceuticals plc, Ireland, + 353 1 634 7887, U.S., + 1 650 496 2717, or Media, Laurie Hurley, Vice President, Corporate Affairs, Jazz Pharmaceuticals plc, Ireland, + 353 1 634 7894, U.S., + 1 650 496 2796